References
  1. Adelberg DE, Bishop MR. Emergencies related to cancer chemotherapy and hematopoietic stem cell transplantation. Emerg Med Clin North Am.2009;27:311-31
  2. Bodey GP, Buckley, M, Sathe YS, Freireich EJ. (1966) Quantative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-40
  3. Wenneras C, Hagberg L, Andersson R, Hynsjö L, Lindahl A, Okroj M, Blom AM, Johansson P, Andreasson B, Gottfries J et al. Distinct Inflammatory Mediator Patterns Characterize Infectious and Sterile Systemic Inflammation in Febrile Neutropenic Hematology Patients, Open Access, www.plosone.org, March 2014, 9 (3), e92319
  4. Bille J. Laboratory diagnosis of infections in febrile neutropenic or immunocompromised patients. Int J Antimicrob Agents.2000;16(2):87-9
  5. Mulinde J, Joshi M. The diagnostic and therapeutic approach to lower respiratory tract infections in the neutropenic patient. J Antimicrob Chemother.1998;41(suppl D):51-5
  6. Juutialinen A, Hamalainen S, Pulkki K Kuittinen T, Nousiainen T, Koivula I. Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis. Leuk Lymphoma, 2011;52:2349-55
  7. Buyukberber N, Buyukberber S, Sevinc A, Camci C. Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients. Med Oncol.2009;26:55-61doi:10.1007/s12032-008-9081-z
  8. Persson L, Engervall P, Magnuson A, Vikerfors T, Söderquist B, Hansson LO, Tidefelt U. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 2004;36:365-71.doi:10.1080/00365540410020217
  9. Kern WV, Heiss M, Steinbach G. Prediction of gram-negative bacteraemia in patients with cancer and febrile neutropenia by means of IL-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis.2001;32:832-35.doi:10.1086/319207
  10. Erel O, Neselioglu S (2014) A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem 47:326–332
  11. Wasterlain CG, Fujikawa DG, Penix L, Sankar R (1993) Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 34:37–53
  12. Horton JW. Free radicals and lipid peroxidation mediated injury in burn trauma: The role of antioxidant therapy. Toxicology 2003;189(1-2):75-88
  13. Ellman G, Lysko H. A precise method for the determination of whole blood and plasma sulfhydryl groups. Anal Biochem. 1979;93:98–102
  14. Sudhoff T, Giagounidis A, Karthaus M, Serum and plasma parameters in clinical evaluation of neutropenic fever Antibiot Chemother, 2000,50;10-19
  15. Carrol ED, Thomson AP, Hart CA. Procalcitonin as a marker of sepsis. Int J Antimicrob Agents.2002;20(1):1-9
  16. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol, 2000, 18(16):3038-51
  17. Carmona-Bayonas A, Jimenez-Fonseca B, Virizuela Echaburu J, Antonio M, Font C, Boisca M, Ramchandani A, Martinez J, Hernando Cubero J, Espinosa J et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Onc,2015 33(5):465-71
  18. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR .Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America, e56 d CID 2011:52 (15 February)
  19. De Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F; Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol,2000,21(suppl 5):252-56,doi:10.1093/annonc/mdq196
  20. LeGrand A, Fermor B, Fink C, Pisetsky DS, Weinberg JB, Vail TP, Guilak F. Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum 2001;44(9):2078-83
  21. Groitl B, Jakob U. Thiol-based redox switches. Biochim Biophys Acta 2014;1844:1335–1343
  22. Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogesang H, Junker U, Jager L, Reinhart K. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro.J Lab Clin Med,1999,134;49-55
  23. Meisner M, Muller V, Khakpour Z, Toegel E, Redl H. Induction of procalcitonin and proinflammatory cytokines in an anhepatic baboon endotoxin shock model.Shock,2003,19:187-90
  24. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta.2002;323(1-2):17-29
  25. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection, 2008,36(5):396-407.doi:10.1007/s15010-008-7374-y
  26. Wu CW, Wu JY, Chen CK, Huang SL, Hsu SC, Lee MT, Chang SS, Lee CC. Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer,2015;23:2863-72
  27. Luz Fiusa MM, Costa Lima C, de Souza GR, Vigorito AC, Penteado Aranha FJ, Lorand-Metze I, Annichino-Bizzacchi JM, de Souza CA, De Paula EV. A high angiopoetin2/angiopoetin1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Crit Care 2013;17:R169
  28. Alves BE, Montalvao SA, Aranha FJ Siegl TF, Souza CA, Lorand-Metze I, Annichino-Bizzacchi JM, De Paula EV. Imbalances in serum angiopoetin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia. BMC Infect Dis 2010;10:143
  29. Ruokonen E, Nousiainen T, Pulkki K, Takala J. Procalcitonin concentrations in patients with neutropenic fever. Eur J Clin Microbiol Infect Dis,1999,18(4);283-85
  30. Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ.2013;16 (6):720-35. doi: 10.3111/13696998.2013.782034
  31. Yetkin F, Senol E, Yalçın S, Haznedar R. The Evaluation of Procalcitonin as a Diagnostic and Prognostic Marker of Bacterial Infections in Febrile Neutropenic Patients. Klimik Dergisi 2011;24(1):24-30
  32. Coyne JC,BS Le Vivian, Brennan JJ, Castillo EM, Shatsky RA, Ferran K, Brodine S, Vilke GM . Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department. Annals of Emergency Medicine,Volume 69,No:6:June 2017
  33. Rast AC, Kutz A, Felder S, Faessler L, Steiner D, Laukemann S, Haubitz S, Huber A, Buergi U, Conca A. Procalcitonin Improves the Glasgow Prognostic Scale for Outcome Prediction in Emergency Patients with Cancer: a Cohort Study, Dis Markers, 2015, E Pub
  34. Sedef AM, Köse F, Mertsoylu H, Ozyılkan O. Procalcitonin as a biomarker for infection related mortality in cancer patients. Curr Opin Support Pall Care,2015;9:168-73
  35. Massaro KSR, Macedo R, de Castro BS, Dulley F, Oliveira MS, Yasuda MA, Levin AS, Costa SF. Risk factor for death in hematopoietic stem cell transplantation: are biomarkers useful to forsee the prognosis in this population of patients? Infection 2014,42:1023-32
  36. Ortega M, Rovira M, Almela M, de la Bellacasa JP, Carreras E, Mensa J . Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. Bone Marrow Transplantation 2004;33:741-44
  37. Ahn S, Lee YS, Lee JL, Lim KS, Yoon SC. A new prognostic model for chemotherapy-induced febrile neutropenia. Int J Clin Oncol.2016:21:46-52
  38. Ha YE, Song JH, Kang WK, Peck KR, Chung DR, Kang CI, Joung MK, Joo EJ, Shon KM. Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy. Support Care Cancer.2011;19:1761-67
  39. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J. Management of febrile neutropenia : ESMO Clinical Practice Guidelines. Ann Oncol. 2016:27;111-118
  40. Combariza JF, Lombana M, Pino EL, Arango M. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms. Support Care Cancer 2015, 23:1009-13
  41. Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin C-reactive protein, serum amyloid A, and interleukins-1β,-6,-8 and 10 European Journal of Cancer Care,2007;16:475-483
  42. Ahn S, Lee YS, Lim KS, Lee JL. Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer, 2013,21:2303-08
  43. Klastersky J,Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents.2007:30 (suppl 1):51-9
  44. Viscoli C, Cometta A, Kern WV, Bock R, Paesmans M, Crokaert F, Glauser MP, Calandra T . Piperaccilin-tazobactam monotherapy in high risk febrile neutropenic cancer patients. Clin Microbiol Infect 2006;12:212-16
  45. Rintala E, Irjala K, Nikoskelainen J. Value of measurement of C-reactive protein in febrile patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 1992;11:973-78
  46. Kern WV. Risk assessment and treatment of low risk patients with febrile neutropenia. Clin Infect Dis 2006;42:533-40
  47. Prat C,Sancho MJ, Dominguez J, Xicoy B, Gimenez M, Ferra C, Blanco S, Lacoma A, Ribera JM, Ausina V. Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leukemia and Lymphoma, 2008 September;49(9):1752-61
Tables
Table 1. The Multinational Association for Supportive Care in Cancer (MASCC) Score